|Articles|May 23, 2018
The Fundamental Disconnect Between Pharma and Technology
Author(s)Michelle Maskaly
Otsuka Pharmaceutical’s President and CEO of Development and Commercialization William Carson explains the initial growing pains the company went through with their technology company partner in the early development stages of the first U.S. FDA approved digital medicine system.
Advertisement
Otsuka Pharmaceutical’s President and CEO of Development and Commercialization William Carson explains the initial growing pains the company went through with their technology company partner in the early development stages of the first U.S. FDA approved digital medicine system, Abilify Mycite.
His interview was recorded during the May 2018 Financial Times Live ‘s US Healthcare & Life Sciences Summit in New York City.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Partnership
2
Why Integrated GMP Operating Models Are Reshaping Outsourced Manufacturing
3
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
4
Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline
5